title: The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing.
abstract: OBJECTIVE
  To review the changing treatment paradigm for newly diagnosed multiple myeloma and its implications for nursing.
  
  
  METHODS
  Journal articles, textbooks, published research data.
  
  
  RESULTS
  The treatment approaches to newly diagnosed multiple myeloma are varied, and no consensus exists about the best choice of induction therapy prior to high-dose chemotherapy with autologous stem cell transplantation. Novel therapies that have shown strong clinical activity in patients with relapsed or refractory myeloma currently are being explored as first-line therapy with associated higher incidence of serious complications.
  
  
  CONCLUSIONS
  Novel approaches in the treatment of newly diagnosed multiple myeloma may lead to better overall patient survival. Research is ongoing to find ways to improve progression-free and overall survival in patients with multiple myeloma.
  
  
  CONCLUSIONS
  Oncology nurses play vital roles in the assessment and monitoring of serious complications associated with various therapies for patients with newly diagnosed multiple myeloma. Key responsibilities include safe and effective administration of complex chemotherapeutic regimens, management of side effects, patient and family education, and coordination of a multidisciplinary approach.
authors.affiliation: Multiple Myeloma Program of the Department of Medicine in the Division of Hematology/Oncology at Northwestern University Medical Faculty Foundation, Chicago, IL, USA. jtariman@nmff.org
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Tariman
authors.forename: Stella Marie
authors.initials: SM
authors.lastname: Estrella
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000175:diagnosis / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D009367:Neoplasm Staging; D009859:Oncology Nursing / Q000379:methods*; D033581:Stem Cell Transplantation / Q000451:nursing; D014182:Transplantation, Autologous / Q000451:nursing
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007155:Immunologic Factors